Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 23 analysts that cover Regeneron Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $842.13, which forecasts a 20.61% increase in the stock price over the next year. The lowest target is $627 and the highest is $1,057.

Price Target: $842.13 (+20.61%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$627	$842.13	n/a	$1,057
Change	-10.20%	+20.61%	n/a	+51.38%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	8	9	9	9	10	9
Buy	7	8	7	9	8	8
Hold	7	7	6	6	6	5
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	23	25	23	25	25	23

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Yatin Suneja Guggenheim	Guggenheim	Strong Buy Maintains $975 → $995	Strong Buy	Maintains	$975 → $995	+42.50%	May 1, 2026
Brian Abrahams RBC Capital	RBC Capital	Hold Maintains $779 → $762	Hold	Maintains	$779 → $762	+9.13%	Apr 30, 2026
Eliana Merle Barclays	Barclays	Buy Maintains $923 → $917	Buy	Maintains	$923 → $917	+31.33%	Apr 30, 2026
Gregory Renza Truist Securities	Truist Securities	Strong Buy Maintains $801 → $796	Strong Buy	Maintains	$801 → $796	+14.00%	Apr 30, 2026
Mohit Bansal Wells Fargo	Wells Fargo	Hold Maintains $825 → $800	Hold	Maintains	$825 → $800	+14.57%	Apr 30, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

16.23B

Increased by 13.14%

from 14.34B

Revenue Next Year

17.98B

Increased by 10.82%

from 16.23B

EPS This Year

47.12

Increased by 13.59%

from 41.48

EPS Next Year

55.55

Increased by 17.90%

from 47.12

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	16.07B	12.17B	13.12B	14.20B	14.34B	16.23B	17.98B
Revenue Growth	89.14%	-24.26%	7.76%	8.27%	0.99%	13.14%	10.82%
EPS	71.97	38.22	34.77	38.34	41.48	47.12	55.55
EPS Growth	135.81%	-46.90%	-9.03%	10.27%	8.19%	13.59%	17.90%
Forward PE	-	-	-	-	-	14.82	12.57
No. Analysts	-	-	-	-	-	31	30

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	18.0B	20.1B
Avg	16.2B	18.0B
Low	14.4B	16.0B

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	25.8%	23.8%
Avg	13.1%	10.8%
Low	0.3%	-1.7%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	56.29	65.63
Avg	47.12	55.55
Low	37.10	42.83

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	35.7%	39.3%
Avg	13.6%	17.9%
Low	-10.6%	-9.1%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.